Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK To Go Ahead With Pre-Licensing Use Of COVID-19 Vaccines

Govt Addresses Concerns Over Safety, Liability and Workforce Expansion

Executive Summary

A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded. 

You may also be interested in...



UK Vaccine Taskforce Leader Under Scrutiny After Investor Meeting

The UK has built one of the biggest and best ‘portfolios’ of COVID-19 vaccine candidates – but there are questions about its transparency and accountability.

UK Authorizes Use Of Unlicensed Flu Vaccine

A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.

BIA Applauds UK Plan For Pre-Approval Use Of Coronavirus Vaccine

The UK can already OK the use of unapproved products, but the government wants more certainty around the conditions that will be attached to any decision to make COVID-19 vaccines available before they have been licensed. Moves are also under way to reassure pharmaceutical companies about liability issues.

Topics

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel